What's trending, explained.
What's trending, explained.
The Defense Health Agency has released clinical guidance implementing Defense Secretary Pete Hegseth's July order to screen male service members for testosterone deficiency. Under the new policy, men aged 30 and older will be routinely screened; younger men may request screening; women are not included for now. Screening takes place on two separate mornings, and those falling below 300 nanograms per deciliter — the standard medical threshold — are assessed for further evaluation. Treatment is optional and can involve weekly or biweekly injections, a daily oral medication, or a gel. It will not be mandatory.
The policy drew sharp new scrutiny on October 15 with the publication of a research letter in JAMA analyzing data from the Military Health and Nutrition Examination study, a survey conducted at five Army bases from August 2024 through January 2026. The researchers found a weighted mean morning total testosterone of 405 ng/dL. Extrapolating that data to the entire active-duty Army population at the Pentagon's 300 ng/dL cutoff, they estimated that about 26 percent of soldiers would get a test result suggesting low testosterone.
The authors added two important cautions. First, a low screening result does not mean a soldier has hypogonadism, the medical condition of clinically deficient testosterone. Second, the screening could generate substantial follow-on costs: excess medical visits, diagnostic workups, and treatment. For context, a separate analysis found that just 0.43 percent of active-duty men — 12,112 of more than 2.8 million service members — had actually been diagnosed with hypogonadism, with the highest rates among the most senior ranks.
Hegseth has framed the program as a readiness measure, saying it is about restoring troops' natural capabilities and the biological foundation needed to sustain and fight. But medical groups generally do not recommend automatic testosterone screening. Standard guidelines call for testing men who report symptoms and then confirming low levels with two blood tests — a narrower approach than the Pentagon's population-wide screening. The Associated Press has noted that the push arrives alongside a wave of online interest in testosterone driven by men's-health influencers and podcasters, part of a $4.5 billion testosterone-replacement industry.
The gap between 26 percent and 0.43 percent is the heart of this story. A screening cutoff is not a diagnosis: many healthy men fall below 300 ng/dL on a given morning without having hypogonadism, and the JAMA authors explicitly warn against reading a flagged test as a disease. If a quarter of the Army gets flagged, the military health system could be pulled into an enormous program of repeat testing, specialist referrals, and treatment — with costs and side effects to match.
The side effects are real. For severe, medically diagnosed hypogonadism, treatment can cause mood swings, irritability and aggression, blood clots, and low sperm count that can cause infertility. And the benefits are narrower than marketing suggests: a 2018 NIH study of 800 older men found testosterone therapy improved erectile dysfunction, libido, and mood, but showed little or no improvement in fatigue, memory, or overall well-being.
There is also a question of what low testosterone in troops actually signals. Environmental exposures, combat, physical injuries, sleep deprivation, and mental health conditions can all contribute to depressed testosterone levels in service members. If the underlying drivers are chronic sleep loss and operational stress, hormone treatment addresses the symptom rather than the cause — and the vague symptom checklist in the screening guidance (diminished physical performance, disturbed sleep, low motivation) could sweep in soldiers whose real problems are exhaustion, injury, or mental health.
Culturally, the program is inseparable from Hegseth's broader "warrior ethos" campaign — fitness standards, grooming rules, and now hormones as a marker of military virtue. Critics, including national-security analysts interviewed by NPR, argue the focus on toughness aesthetics distracts from modernization and warfighting; supporters say a military that screens and optimizes its people is simply taking readiness seriously. Both sides are really arguing about what readiness means in 2026.
One note of professional caution: none of this is personal medical advice. Testosterone levels fluctuate, symptoms like fatigue and poor sleep have many causes, and anyone with concerns about hormone health should talk to a clinician rather than drawing conclusions from a policy debate.
The guidance is now the rule, so the next data will come from implementation: how many service members actually get screened, how many flag low, how many choose treatment, and what it costs the military health system. Researchers and medical groups will be watching for signs of overtreatment — and for whether the program gets expanded to women, who were covered in Hegseth's original memo but excluded from the current guidance.
Congressional oversight is possible, particularly if costs balloon or if the screening produces the flood of follow-on care the JAMA authors predict. And the broader cultural argument — whether the Pentagon is optimizing warfighters or medicalizing morale — is unlikely to end with a clinical guideline. The JAMA letter has given that debate its first hard numbers; the Pentagon's response to them will be the next chapter.